US-based life science company Meridian Bioscience has developed its new illumigene Malaria molecular-based, field laboratory-deployed test to diagnose malaria.

In comparison with existing tests, illumigene Malaria is claimed to be around 80,000 times more sensitive at detecting the parasite.

It employs loop-mediated isothermal amplification (LAMP) technology to amplify DNA and detect the parasite.

The Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal, provided technical assistance for the development of the test.

Meridian Bioscience research and development executive vice-president Slava Elagin said: “People can be carriers of malaria without showing any symptoms, so detecting these individuals can be challenging.

“If testing doesn’t identify them, eliminating malaria is impossible because these individuals can spread the disease to others.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Molecular testing is considered to be more effective in the detection of very low levels of malaria parasites, which enables treatment and prevention of the spread of the disease.

The new test can be used in the field laboratory, where there is a particularly high presence of malarial infection that is hard to diagnose and treat.

"In comparison to existing tests, illumigene Malaria is claimed to be around 80,000 times more sensitive at detecting the parasite."

Special training or capital investment is not required for the user-friendly test that provides results within one hour and can be stored at room temperature.

The aim of the new test is to enhance the current testing protocols, instead of replacing them.

When combined with rapid diagnostic tests (RDTs) and microscopy, the test can create a network of detection protocols to help administer treatment appropriately.

Meridian Bioscience Europe will distribute the test in Europe, the Middle East, and Africa, while the firm's global distribution network will supply to other international markets.